Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.73 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.64 |
| ▸ | LCK | P06239 | 1/20 | 0.64 |
| ▸ | FYN | P06241 | 1/20 | 0.64 |
| ▸ | CA4 | P22748 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL27853741 | 1.00 | CA1 (0.73) | CA1FFAR3LCKFYNCA4 | |
| Acetic Acid SCHEMBL27600994 | 1.00 | CA1 (0.73) | CA1FFAR3LCKFYNCA4 | |
| Acetic Acid SCHEMBL28216441 | 0.96 | CA1 (0.67) | CA1FFAR3LCKFYNCA4 | |
| Acetic Acid SCHEMBL28252078 | 0.96 | CA1 (0.75) | CA1FFAR3LCKFYNCA4 | |
| Acetic Acid SCHEMBL20270616 | 0.96 | CA1 (0.67) | CA1FFAR3LCKFYNCA4 | |
| Acetic Acid SCHEMBL6799509 | 0.92 | CA1 (0.69) | CA1FFAR3LCKFYNCA4 | |
| Acetic Acid SCHEMBL23926248 | 0.91 | CA1 (0.73) | CA1FFAR3LCKFYNCA4 | |
| Acetic Acid SCHEMBL7316954 | 0.91 | CA1 (0.82) | CA1FFAR3LCKFYNCA4 | |
| Acetic Acid SCHEMBL11410545 | 0.91 | CA1 (0.73) | CA1FFAR3LCKFYNCA4 | |
| Acetic Acid SCHEMBL431679 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117682553-A | Recycling treatment method for waste lead plaster | 吉林化工学院 | 2024-03-12 | — | — | CN | claimed |
| CN-108950600-B | A kind of electrolyte and electrolytic method of lead bullion electrorefining | 益阳生力材料科技股份有限公司 | 2019-09-13 | — | — | CN | claimed |
| CN-117682553-A | Recycling treatment method for waste lead plaster | 吉林化工学院 | 2024-03-12 | — | — | CN | disclosed |
| CN-108950600-B | A kind of electrolyte and electrolytic method of lead bullion electrorefining | 益阳生力材料科技股份有限公司 | 2019-09-13 | — | — | CN | disclosed |
| CN-108950600-A | A kind of electrolyte and electrolytic method of lead bullion electrorefining | 益阳生力材料科技股份有限公司 | 2018-12-07 | — | — | CN | disclosed |
| CN-106449990-A | Method for producing halogenated caesium lead material for perovskite solar cell | 天津市职业大学 | 2017-02-22 | — | — | CN | disclosed |
| CN-106410044-A | Method of producing methylamine lead halide for perovskite solar cells | 天津市职业大学 | 2017-02-15 | — | — | CN | disclosed |
| US-8889705-B2 | Noscapine analogs and their use in treating cancers | EMORY UNIVERSITY (US) | 2014-11-18 | — | — | US | disclosed |
| US-20130224310-A1 | NOSCAPINE ANALOGS AND THEIR USE IN TREATING CANCERS | EMORY UNIVERSITY (US) | 2013-08-29 | — | — | US | disclosed |
| US-20110274651-A1 | Noscapine and Noscapine Analogs and Their Use in treating Infectious Diseases by Tubulin Binding Inhibition | EMORY UNIVERSITY (US) | 2011-11-10 | — | — | US | disclosed |
| EP-2328578-A2 | NOSCAPINE AND NOSCAPINE ANALOGS AND THEIR USE IN TREATING INFECTIOUS DISEASES BY TUBULIN BINDING INHIBITION | Emory University (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20100227878-A1 | NOSCAPINE ANALOGS AND THEIR USE IN TREATING CANCERS, INCLUDING DRUG-RESISTANT CANCERS | EMORY UNIVERSITY (US) | 2010-09-09 | — | — | US | disclosed |
| WO-2010030582-A2 | NOSCAPINE AND NOSCAPINE ANALOGS AND THEIR USE IN TREATING INFECTIOUS DISEASES BY TUBULIN BINDING INHIBITION | EMORY UNIVERSITY (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227878-A1 | NOSCAPINE ANALOGS AND THEIR USE IN TREATING CANCERS, INCLUDING DRUG-RESISTANT CANCERS | CASP3, BCL3, TOP1 | CA1 2796/4885FFAR3 607/4885LCK 1336/4885 |
| US-20130224310-A1 | NOSCAPINE ANALOGS AND THEIR USE IN TREATING CANCERS | TUBA1C, TUBB1, TUBB3 | CA1 3483/4885FFAR3 4233/4885LCK 3426/4885 |
| US-20110274651-A1 | Noscapine and Noscapine Analogs and Their Use in treating Infectious Diseases by Tubulin Binding Inhibition | NOS1, NOS2, TBCA | CA1 4871/4885FFAR3 4311/4885LCK 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.